Neurizon Therapeutics Limited has released a press release.
Phase II Dog Lymphoma Trial Confirms MPL Clinical Benefit
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- PharmAust Raises $1.873m via an Oversubscribed Placement
- New MPL analogues show greater anti-cancer activity
- New drugs patented for cancer in USA
- Epichem Update - progress on milestones and revenue targets
- Appendix 4C - Quarterly Report & Brief Company Update
Later from Neurizon Therapeutics
- Epichem Awarded One Year Contract Extension from DNDi
- Monepantel reformulation successfully improves dose & taste
- Appendix 4C - Quarterly Report & Shareholders Update
- PharmAust receives $354k R&D Tax Incentive Refund
- Appendix 4D and Half Yearly Report & Accounts
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics